885521-13-1

Basic information

• Product Name: 4-METHOXY-6-(1H)INDAZOLE CARBOXYLIC ACID METHYL ESTER
• Synonyms: Methyl 4-Methoxy-1H-indazole-6-carboxylate;methyl 4-methoxy-2H-indazole-6-carboxylate;4-Methoxy-1H-indazole-6-carboxylic acid methyl ester;4-METHOXY-6-(1H)INDAZOLE CARBOXYLIC ACID METHYL ESTER
• CAS NO: 885521-13-1
• Molecular Formula: C10H10N2O3
• Molecular Weight: 206.2
• Mol File: 885521-13-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-METHOXY-6-(1H)INDAZOLE CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-6-(1H)INDAZOLE CARBOXYLIC ACID METHYL ESTER(885521-13-1)
• EPA Substance Registry System: 4-METHOXY-6-(1H)INDAZOLE CARBOXYLIC ACID METHYL ESTER(885521-13-1)

Safety Data

• Hazardous Substances Data: 885521-13-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Methoxy-6-(1H)indazole carboxylic acid methyl ester is used as an intermediate in the synthesis of pharmaceutical drugs and other organic compounds. Its unique structure and properties make it a valuable component in the development of new medications.
Used in Chemical Research and Development:
4-METHOXY-6-(1H)INDAZOLE CARBOXYLIC ACID METHYL ESTER is also utilized in research and development efforts within the chemical and pharmaceutical industries. Its potential as a precursor to other ester compounds allows for further exploration and innovation in the creation of novel chemical entities.

Upstream product

• 856767-09-4 4-bromo-2-fluoro-6-methoxy-benzaldehyde 
• 885519-21-1 6-bromo-4-methoxy-1H-indazole 
• 201230-82-2 carbon monoxide 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 461-96-1 3,5-difluorobromobenzene 
• 67-56-1 methanol 

Downstream Products

• 1245215-47-7 methyl 4-methoxy-2-methyl-2H-indazole-6-carboxylate 
• 1245215-48-8 methyl 4-hydroxy-2-methyl-2H-indazole-6-carboxylate 

Relevant articles and documents

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus

Glucokinase activators represent a promising potential treatment for patients with Type 2 diabetes. Herein, we report the identification and optimization of a series of novel indazole and pyrazolopyridine based activators leading to the identification of 4-(6-(azetidine-1-carbonyl)-5-fluoropyridin-3- yloxy)-2-ethyl-N-(5-methylpyrazin-2-yl)-2H-indazole-6-carboxamide (42) as a potent activator with favorable preclinical pharmacokinetic properties and in vivo efficacy.

Synthesis of unprotected carboxy indazoles via Pd-catalyzed carbonylation

The first published synthesis of unprotected carboxy indazoles from the corresponding bromoindazoles is described. This is achieved via Pd(II)-catalyzed carbonylation and is demonstrated to work on a variety of indazoles.

SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R4, R6, X, Y and Z are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.